Почетна › Акутна миелоидна леукемија › Тексас › Dallas
Клинички испитувања за Акутна миелоидна леукемија во Dallas, TX
Една студија за Акутна миелоидна леукемија бара учесници на локација во или блиску до Dallas. Отворете ја за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Се регрутираФаза 1
- Children's Medical Center Dallas /ID# 275930, Dallas
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Се регрутираФаза 3
- Baylor University Medical Center, Dallas
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Се регрутираФаза 1
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Се регрутираФаза 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Се регрутираФаза 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Се регрутираФаза 1/2
- Baylor Scott & White Health, Dallas
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Се регрутираФаза 3
- US-Dallas TX-SOUTHWESTERN, Dallas
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Се регрутираФаза 1/2
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Се регрутираФаза 3
- Harold C. Simmons Comprehensive Cancer Center, Dallas
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Се регрутираФаза 3
- Texas Oncology-Presbyterian Cancer Center, Dallas
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Се регрутираФаза 1
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Се регрутираФаза 1
- UT Southwestern/Simmons Cancer Center, Dallas
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Се регрутираФаза 3
- Baylor Charles A. Sammons Cancer Center, Dallas
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Се регрутираФаза 1
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Се регрутираНабљудувачка студија
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Се регрутираФаза 2
- UT Southwestern Medical Center at Dallas, Dallas
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Се регрутираФаза 1
- UT Southwestern Medical Center, Dallas
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Се регрутираФаза 1
- Baylor University Medical Center, Dallas
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Се регрутираФаза 2/3
- University of Texas Southwestern Medical Center, Dallas
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Се регрутираФаза 1
- UT Southwestern - Simmons Cancer Center, Dallas
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Се регрутираФаза 1
- University of Texas Southwestern Medical Center, Dallas
Испитувања за Акутна миелоидна леукемија во други градови
- Houston, TX85 студии
- New York City, NY51 студија
- Boston, MA44 студии
- Seattle, WA41 студија
- Baldwin Park, CA40 студии
- Columbus, OH35 студии
- Philadelphia, PA34 студии
- Durham, NC33 студии
- Atlanta, GA31 студија
- Tampa, FL29 студии
- Chicago, IL26 студии
- Portland, OR25 студии
Други студии во Dallas
- Рак на дојка55 студии
- Рак на бели дробови со не-мали клетки52 студии
- Метастатски карцином42 студии
- Срцева слабост42 студии
- Рак (сите типови)37 студии
- Рак на простата36 студии
- Колоректален карцином33 студии
- Дебелина30 студии
- Карцином на јајниците28 студии
- Рак на бели дробови27 студии
- Рак на бешиката27 студии
- Рак на ендометриумот24 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.